EGFR and non-small cell lung carcinoma: The EMERGING-CTONG 1103 study, a randomized phase II trial, compared neoadjuvant erlotinib 150 mg daily up to 42 days and adjuvant erlotinib up to 12 months with gemcitabine plus cisplatin (2 cycles of neoadjuvant therapy and up to 2 cycles of adjuvant therapy) chemotherapy in patients with stage IIIA N2 EGFR-positive NSCLC [81].